Pressemitteilungen
10.01.2019
Blood of cancer patients contains different types of cancer-derived materials that are susceptible to detailed analysis of tumor disease: intact circulating tumor cells (CTCs), cell-free circulating tumor DNA, tumor educated platelets and extracellular vesicles. Different techniques can isolate those biomarkers and are used as diagnostic and monitoring tools for cancer treatment. These blood-based tests (also called liquid biopsy) are a sensitive and less invasive alternative or complementary approach to tissue biopsies…
13.07.2018
GILUPI announces the release of a video article presenting an innovative approach for isolation of circulating tumor cells (CTCs) by the use of the GILUPI CellCollector® and their downstream phenotyping in combination with chromosomal rearrangement detection [1].
CTCs can often be found in the blood of cancer patients. They are a promising surrogate marker for disease progression and response to therapy…
03.05.2018
GILUPI GmbH is pleased to announce its participation at the 2018 ISMRC (International Symposium on Minimal Residual Cancer) congress.
The 11th ISMRC symposium will take place from 3rd to 5th of May in Montpellier, France and is focused on “Minimal Residual Cancer in patients with solid tumors”. This congress brings together researchers from academia and industry sharing information about liquid biopsy. The program will include presentations on Circulating Tumor Cells (CTCs) as well as circulating nucleic acids (DNA, miRNA) and exosomes…
18.04.2018
GILUPI GmbH announced that the company was granted a European patent protecting the unique and innovative GILUPI technology for the capture of circulating cancer cells (CTCs) and further applications.
The European Patent Office (EPO) issued patent EP2807979 B1 entitled “Detection device for in vivo and/or in vitro enrichment of sample material”. The patent describes a functionalized structured medical wire for the enrichment of sample material. The technology is already being used in clinical settings…
20.02.2018
GILUPI announces the publication of a peer reviewed study about a new and promising mRNA-based assay that allows detection and quantification of clinically relevant prostate and pancreas cancer markers in circulating tumor cells (CTCs)[1].
CTCs are a surrogate marker for cancer progression and response to therapy. CTCs indicate tumor cell spreading and are a prerequisite for…
18.01.2018
GILUPI GmbH announces that Dr. Christian Jurinke is appointed to the position of CEO and together with Alexander Herrmann is now managing the company.
Alexander Herrmann, Managing Director of GILUPI, stated „Dr. Jurinke is an accomplished expert when it comes to the development and commercialization of innovative products in the field of cancer molecular diagnostics…
14.12.2017
GILUPI GmbH announces the recent publication of a clinical study demonstrating multiplex gene expression profiling of circulating tumor cells (CTCs) isolated in vivo from high-risk prostate cancer patients by the use of GILUPI CellCollector® [1].
Prostate cancer is a very common cancer and accounts for one of the most related cancer deaths among men. About 15%-30% of patients with prostate cancer are diagnosed with high-risk disease…
01.11.2017
GILUPI GmbH announces the release of a scientific article about the detection of circulating tumor cells (CTCs) from blood of different groups of pulmonary disease patients by the use of GILUPI CellCollector® [1].
Lung cancer is worldwide the most common cause of cancer-related death in men with a five-year survival rate lower than 20%. Two of three lung cancer patients have an advanced stage disease at initial diagnosis…
21.09.2017
GILUPI GmbH is pleased to announce its participation at the 2017 ACTC (Advances in Circulating Tumor Cells) congress.
The 3rd ACTC meeting will take place from 4th to 7th October in Rhodes, Greece and is focused on “Liquid Biopsy in clinical practice”. This congress brings together researchers, clinicians and companies, to discuss practical implementation of CTCs (circulating tumor cells) and ctDNA (circulating tumor DNA) and translate much of the excellent basic research …
06.09.2017
GILUPI GmbH announces the recent publication of a clinical study demonstrates the isolation of circulating tumor cells (CTCs) from blood of squamous cell carcinoma of head and neck (SCCHN) patients with the GILUPI CellCollector® [1].
Isolating and analyzing CTCs from the blood of cancer patients can provide additional information on prognosis, course of disease, treatment efficacy and molecular tumor evolution…
09.08.2017
GILUPI GmbH announces that a scientific article about a multicenter, clinical trial in China has been published in the current issue of “National Medical Journal of China”. The scientific paper demonstrates the isolation of circulating tumor cells (CTCs) from blood of breast cancer patients with the GILUPI CellCollector® [1].
Isolating and analyzing CTCs from the blood of cancer patients can provide additional information on prognosis of patients, treatment efficacy…
06.07.2017
The GILUPI CellCollector® – the first medical device for in vivo CTC isolation, manufactured by GILUPI – has been approved by the Chinese registrations agency (China Food and Drug Administration – CFDA) in June. As a result, the Potsdam-based company gains access to one of the most significant geographical markets worldwide. This milestone was reached in close cooperation with GILUPIs strategic partner, Hebei Viroad Biotechnology Co. Ltd. (Viroad). Besides its role as strategic partner, Viroad is also the largest investor and shareholder of GILUPI…
12.04.2017
GILUPI GmbH, a developer and manufacturer of medical devices to enrich circulating tumor cells (CTCs) directly from the blood of cancer patients, announces that Alexander Herrmann has been designated to the position as managing director of the GILUPI GmbH effective April 2017.
Having an apprenticeship as banker and a master degree in Business Administration, Alexander Herrmann (44) counts many years of experience in leadership ….
22.03.2017
GILUPI GmbH announced today that the company was granted a further Chinese patent protecting the unique and innovative GILUPI technology.
The patent (ZL201180024406.8), short titled “biodetector” is valid until 15 March 2031. The newly granted Chinese patent extends GILUPIs patent portfolio protecting next device generations with enhanced sensitivity and greater convenience for patients…
25.01.2017
GILUPI GmbH announces the release of clinical data from a prostate cancer clinical study in December 2016. The scientific paper demonstrates the isolation of circulating tumor cells (CTCs) from blood of non-metastatic high-risk prostate cancer patients with the GILUPI CellCollector® [1].
Liquid biopsy – isolating and analyzing circulating tumor cells (CTCs)…
14.12.2016
The investors AURELIA, High-Tech Gründerfonds (HTGF), KfW, ILB, the – venture capital fund of the Sparkassen of Brandenburg and Business Angels sell their GILUPI shares to the strategic partner VIROAD.
GILUPI is a company developing and manufacturing personalized cancer diagnostics in Potsdam. Due to the takeover, GILUPI gets the opportunity to continue the development of its medical products and to diversify their range of products through in vitro diagnostics. At the same time, the transaction allows …
19.10.2016
GILUPI GmbH announces the release of clinical data from a prostate cancer setting in August 2016. The scientific paper demonstrate the isolation of circulating tumor cells (CTCs) from blood of prostate cancer patients with GILUPI CellCollector®.
Liquid biopsy – isolating and analyzing circulating tumor cells (CTCs) from the blood of prostate cancer patients – can provide additional information …
15.09.2016
GILUPI GmbH announces, that in August 2016 a published scientific paper demonstrated for the first time circulating tumor cell (CTCs) isolation in neuroendocrine tumor patients with GILUPI CellCollector®.
Isolating and analyzing circulating tumor cells as a “liquid biopsy” can be an additional source of diagnosis, prognosis, evaluation of treatment efficacy and molecular tumor evolution and metastatic sites …